Search research articles
Contact Us
Filters
Showing results (71-80 of 107) with videos related to
Page
of 11
Sort By:
JCO Precision Oncology
|
June 12, 2026
Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study
Mohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Gynecologic Oncology
|
March 2, 2021
Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study
Katharina Prieske, Linn Woelber, Mustafa Zelal Muallem, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology
|
February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
Felicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
The Lancet. Oncology
|
July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Amit M Oza, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology
|
July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander, Val Gebski, Emma Gibbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Jonathan A Ledermann, Christian Marth, Mark S Carey, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Domenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 107) with videos related to
Sort By:
Page
of 11
JCO Precision Oncology
|
June 12, 2026
Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study
Mohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Gynecologic Oncology
|
March 2, 2021
Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study
Katharina Prieske, Linn Woelber, Mustafa Zelal Muallem, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology
|
February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
Felicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
The Lancet. Oncology
|
July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Amit M Oza, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology
|
July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander, Val Gebski, Emma Gibbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Jonathan A Ledermann, Christian Marth, Mark S Carey, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Domenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Page
of 11